Active	Status	Sponsor type	Region	Phase	Filter
7 Active 1 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Minniti, Giuseppe
USZ-STRIKE, NCT05522660: Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer	Recruiting	3	190	Europe	Stereotactic radiosurgery, Immune checkpoint inhibitor, standard of care treatment	ETOP IBCSG Partners Foundation, USZ Foundation	Non-Small Cell Lung Cancer, Melanoma	01/26	12/26
LEGATO, NCT05904119: Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study	Recruiting	3	411	Europe	Lomustine, Reirradiation	European Organisation for Research and Treatment of Cancer - EORTC	First Progression of Glioblastoma	09/27	02/28
MIRAGE, NCT06275919: Regorafenib for Recurrent Grade 2 and 3 Meningioma ( Trial)	Not yet recruiting	2	104	Europe	Regorafenib 40 MG Oral Tablet, Local Standard of Care	Istituto Oncologico Veneto IRCCS, Bayer	Meningioma, Malignant	12/26	03/27
SURE-AVR, NCT02679404: Sorin Universal REgistry on Aortic Valve Replacement	Terminated	N/A	2758	Europe, Canada, US, RoW		Corcym S.r.l	Aortic Valve Disease, Aortic Stenosis	03/21	03/21
NCT04810182: Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS	Completed	N/A	192	Europe	Regorafenib 40 MG Oral Tablet [STIVARGA]	Istituto Oncologico Veneto IRCCS	Glioblastoma Multiforme	12/23	12/23
MANTRA, NCT05002543: CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting	Recruiting	N/A	2150	Europe, Canada, US, RoW		Corcym S.r.l	Cardiac Valve Disease	08/25	12/35
Nevinny-Stickel, Meinhard
LEGATO, NCT05904119: Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study	Recruiting	3	411	Europe	Lomustine, Reirradiation	European Organisation for Research and Treatment of Cancer - EORTC	First Progression of Glioblastoma	09/27	02/28